HLS Therapeutics completes going public transaction

On March 12, 2018, HLS Therapeutics Inc. (HLS:TSXV) announced the completion of a reverse take-over of TSXV-listed Automodular Corp. to conclude HLS’s going-public transaction. The transaction was implemented by way of a Court-approved plan of arrangement under the OBCA. HLS had previously completed in 2015 a private placement transaction of equity and debt that raised US$385 million. HLS is an international specialty pharmaceutical company focused on acquiring and commercializing clinically differentiated pharma products in the specialty central nervous system and cardiovascular markets. HLS is led by former Biovail Corp. executives Bill Wells (Chairman), Gregory Gubitz (Chief Executive Officer) and Gilbert Godin (President). 

HLS was advised by Blake, Cassels & Graydon LLP with a team comprising David Toswell, Catherine Youdan, Liam Churchill, Linda Tu, Hani Migally, Andrew Wang and Yasmina Mavani (securities), Fabien Lanteri-Massa (financial services), Chris van Loan and Ian Caines (tax) and Ryan Morris (litigation). 

Automodular was advised by Fasken Martineau DuMoulin LLP with a team comprising Aaron Atkinson, Bradley Freelan, David Steinhauer and Jeremy Mandel (securities), Jon Holmstrom (banking), Ronald Nobrega (tax) and Brad Moore (litigation).